These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

903 related articles for article (PubMed ID: 26840085)

  • 41. Modeling tumors of the peripheral nervous system associated with Neurofibromatosis type 1: Reprogramming plexiform neurofibroma cells.
    Mazuelas H; Carrió M; Serra E
    Stem Cell Res; 2020 Dec; 49():102068. PubMed ID: 33160273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol.
    Shen YC; Upadhyayula R; Cevallos S; Messick RJ; Hsia T; Leese MP; Jewett DM; Ferrer-Torres D; Roth TM; Dohle W; Potter BV; Barald KF
    Br J Cancer; 2015 Oct; 113(8):1158-67. PubMed ID: 26461061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
    PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
    Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
    Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.
    Park GH; Lee SJ; Yim H; Han JH; Kim HJ; Sohn YB; Ko JM; Jeong SY
    Oncol Rep; 2014 Oct; 32(4):1347-54. PubMed ID: 25109740
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
    Malone CF; Fromm JA; Maertens O; DeRaedt T; Ingraham R; Cichowski K
    Cancer Discov; 2014 Sep; 4(9):1062-73. PubMed ID: 24913553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.
    Ahsan S; Ge Y; Tainsky MA
    Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Calebin-A induced death of malignant peripheral nerve sheath tumor cells by activation of histone acetyltransferase.
    Lee MJ; Tsai YJ; Lin MY; You HL; Kalyanam N; Ho CT; Pan MH
    Phytomedicine; 2019 Apr; 57():377-384. PubMed ID: 30831486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
    Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
    Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks AA; Cantor A; Korf B; Perentesis J; Gutmann DH; Schorry E; Packer R; Fisher MJ
    Pediatr Blood Cancer; 2014 Jun; 61(6):982-6. PubMed ID: 24851266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma.
    Hirbe AC; Dahiya S; Miller CA; Li T; Fulton RS; Zhang X; McDonald S; DeSchryver K; Duncavage EJ; Walrath J; Reilly KM; Abel HJ; Pekmezci M; Perry A; Ley TJ; Gutmann DH
    Clin Cancer Res; 2015 Sep; 21(18):4201-11. PubMed ID: 25925892
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
    Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
    Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.
    Kazmi SJ; Byer SJ; Eckert JM; Turk AN; Huijbregts RP; Brossier NM; Grizzle WE; Mikhail FM; Roth KA; Carroll SL
    Am J Pathol; 2013 Mar; 182(3):646-67. PubMed ID: 23321323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
    Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N
    Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.
    Lévy P; Vidaud D; Leroy K; Laurendeau I; Wechsler J; Bolasco G; Parfait B; Wolkenstein P; Vidaud M; Bièche I
    Mol Cancer; 2004 Jul; 3():20. PubMed ID: 15255999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
    Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
    English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD
    Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.